TY - JOUR
T1 - Immune response, diagnosis and treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis lung disease
AU - Eickmeier, Olaf
AU - Rieber, Nikolaus
AU - Eckrich, Jonas
AU - Hector, Andreas
AU - Graeppler-Mainka, Ute
AU - Hartl, Dominik
PY - 2013
Y1 - 2013
N2 - Patients with cystic fibrosis (CF) suffer from chronic infective lung disease, which determines morbidity and mortality. While bacteria, such as Pseudomonas aeruginosa, are well-known to contribute to pulmonary pathology, the relevance of fungi in CF airways remains poorly understood. The best studied fungus in CF is Aspergillus fumigatus, which frequently colonizes CF airways and causes a disease condition termed allergic bronchopulmonary aspergillosis. This review aims to provide an update on the immunological mechanisms, diagnostic approaches and therapeutic strategies for allergic bronchopulmonary aspergillosis and other Aspergillus fumigatusmediated phenotypes in CF lung disease.
AB - Patients with cystic fibrosis (CF) suffer from chronic infective lung disease, which determines morbidity and mortality. While bacteria, such as Pseudomonas aeruginosa, are well-known to contribute to pulmonary pathology, the relevance of fungi in CF airways remains poorly understood. The best studied fungus in CF is Aspergillus fumigatus, which frequently colonizes CF airways and causes a disease condition termed allergic bronchopulmonary aspergillosis. This review aims to provide an update on the immunological mechanisms, diagnostic approaches and therapeutic strategies for allergic bronchopulmonary aspergillosis and other Aspergillus fumigatusmediated phenotypes in CF lung disease.
KW - Allergic Bronchopulmonary Aspergillosis (ABPA)
KW - Cystic fibrosis
KW - Immune response
UR - http://www.scopus.com/inward/record.url?scp=84878668026&partnerID=8YFLogxK
U2 - 10.2174/13816128113199990349
DO - 10.2174/13816128113199990349
M3 - Review article
C2 - 23278535
AN - SCOPUS:84878668026
SN - 1381-6128
VL - 19
SP - 3669
EP - 3678
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 20
ER -